Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 14;21(12):138.
doi: 10.1007/s11886-019-1227-4.

How To Assess a Claudication and When To Intervene

Affiliations
Review

How To Assess a Claudication and When To Intervene

Prio Hossain et al. Curr Cardiol Rep. .

Abstract

Purpose of the review: Peripheral artery disease (PAD) affects close to 200 million people worldwide. Claudication is the most common presenting symptom for patients with PAD. This review summarizes the current diagnostic and treatment options for patients with claudication. Comprehensive history and physical examination in order to differentiate between claudication secondary to vascular disease vs. neurogenic causes is paramount for initial diagnosis. Ankle-brachial index is the most commonly used test for screening and diagnostic purposes. Treatment consists of four different approaches, which are best utilized in combination: non-pharmacological treatment for claudication improvement, pharmacological treatment for claudication improvement, pharmacological treatment for secondary risk reduction, and interventional treatment for claudication improvement.

Recent findings: Cilostazol is the only Food and Drug Administration (FDA)-approved agent for symptomatic treatment of claudication. Supervised exercise programs provide the maximum benefit for claudication improvement, but home-based exercise programs are an alternative. High-intensity statins and an antiplatelet agent should be prescribed to all patients with PAD. Angiotensin-converting-enzyme inhibitors can provide additional risk reduction, especially in patients with diabetes or hypertension. Rivaroxaban of low dosage (2.5 mg twice daily) in combination with aspirin further decreases cardiovascular risk, but this reduction comes at the cost of higher bleeding risk. Peripheral artery disease (PAD) is a form of atherosclerotic disease that affects hundreds of millions of people worldwide-one of its most common manifestations is intermittent claudication (IC), which results from insufficient blood flow to meet the metabolic demands of an affected extremity. This paper reviews the current literature regarding the workup, diagnosis, diagnostic modalities, treatment options, and management of intermittent claudication.

Keywords: Claudication; Medical management; Peripheral artery disease; Peripheral interventions.

PubMed Disclaimer

References

    1. Circulation. 2013 Nov 12;128(20):2241-50 - PubMed
    1. Acta Med Scand. 1987;221(3):253-60 - PubMed
    1. JACC Cardiovasc Interv. 2017 Apr 10;10(7):712-724 - PubMed
    1. Eur Heart J. 2018 Mar 1;39(9):763-816 - PubMed
    1. World J Diabetes. 2015 Jul 10;6(7):961-9 - PubMed

MeSH terms

Substances

LinkOut - more resources